How is next-generation protein sequencing democratizing protein sequencing?

In this interview, NewsMedical speaks with Jeff Hawkins, CEO of Quantum-Si, about the challenges of conventional proteomic methods, as well as how next-generation protein sequencing is democratizing protein sequencing.

Takeda says TYK2 drug it purchased for $4B has passed another mid-stage test

Takeda announced Monday morning that the TYK2 inhibitor it bought from Nimbus Therapeutics for $4 billion has succeeded in a Phase IIb trial in psoriatic

September 12, 2023

Delix plans further trials with neuroplastogen after positive Phase I data – Pharmaceutical Technology

DLX-001 is a neuroplastogen designed to promote neuroplasticity without giving rise to the deleterious attributes of first- and second-generation psychedelics. Credits: 15Studio/Shutterstock.com Delix Therapeutics is

July 15, 2024

Family’s rare telomere mutation reveals new insights into telomere flexibility and disease

Researchers discovered a rare telomere mutation (TTAGGT) in a family, revealing that human telomeres can tolerate non-canonical sequences, impacting telomere maintenance and disease.

June 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.